XEN1101
Phase 3Small molecule
XEN1101 is one of 53 small molecule programs targeting Focal Epilepsy. It is currently in Phase 3.
4
Indications
7
Total Trials
4
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Tegretol
NovartisApproved
Vimpat
UCBApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Lexapro
AbbVieApproved
Thalomid
Bristol-Myers SquibbApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Lanoxin
AAdvanz Pharma
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Major Depressive Disorder2 trials
Focal-onset seizure2 trials
Focal Epilepsy1 trial
Tonic-Clonic Seizures1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XEN1101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- XXenon Pharmaceuticals Inc.